|  |  |
| --- | --- |
| **FOI NO: 1523** | **Date Received: 01 May 2020** |
| **Request :**  1. Please provide the highest, lowest, average (mean) and median actual weekly fees paid to older person’s care providers under a Continuing Healthcare (CHC) package in 2019/20 and 2020/21  a. Older person’s residential  b. Older person’s residential EMI  c. Older person’s nursing  d. Older person’s nursing EMI    2. Please provide the annual number of people aged 65 and over funded by the CCG under a Continuing Healthcare (CHC) package in an older person’s care home for 2018/19, through to 2020/21 | |
| **Response :**  All rates for Residential and Nursing Placements are agreed with the local authority for our framework of providers. There is a set rate for these placements as shown in the table under the median value.    The number of patients who were fully CHC funded or Fast Track patients for each year in a nursing or residential setting is as shown below. Please note due to current COVID guidelines assessments are not being carried out so I am unable to provide you with any figures relating to 2020/21. | |

|  |
| --- |
| **FREEDOM OF INFORMATION REQUESTS MAY** |

|  |  |
| --- | --- |
| **FOI NO: 1524** | **Date Received: 03 May 2020** |
| **Request :**  Can you please provide me with the following?  1- Contact details for the medicines’ management lead on vitamin D for the CCG.  2- A copy of the latest vitamin D guidance used by the CCG for both adults and children.  3- Any guidance or leaflets provided by the CCG regarding advice to patients on OTC or maintenance vitamin D supplementation. | |
| **Response :**  1-      Contact details for the medicines’ management lead on vitamin D for the CCG.  There is no specific MM lead for  Vitamin D . Queries in respect of its prescription/use  should be directed  to general medicines management team -  [barnccg.mmtvisitrequests@nhs.net](mailto:barnccg.mmtvisitrequests@nhs.net)    2-      A copy of the latest vitamin D guidance used by the CCG for both adults and children.  See below link to the  latest guidance for management of low levels of Vitamin D, however this is currently undergoing review . A reviewed draft version was available prior to the beginning of the COVID-19 Pandemic but is not finalised for publication - <https://best.barnsleyccg.nhs.uk/clinical-support/medicines/prescribing-guidelines/Vit_D_Management_Guideline.pdf>​    3-      Any guidance or leaflets provided by the CCG regarding advice to patients on OTC or maintenance vitamin D supplementation.​ Vitamin D is included within the "Guidance on conditions for which over the counter items should not routinely be prescribed in primary care​" The full NHS England guidance is available at: <https://www.england.nhs.uk/wp-content/uploads/2018/03/otc-guidance-for-ccgs.pdf> Barnsley CCG has made the decision to adopt all of the recommendations within this NHSE guidance. A link to Barnsley local OTC guidance is below and reference to Vitamin D is on page 6 of this guidance.  No other advice, leaflets or guidance has been developed. Locally the CCG has used national campaign materials.  <https://best.barnsleyccg.nhs.uk/clinical-support/medicines/prescribing-guidelines/Self_Care_Guidance.pdf>​   There is a 569 million reasons SYB regional campaign and the CCG has also used some of its general  leaflets and resources locally.  [http://569millionreasons.co.uk](http://569millionreasons.co.uk/) | |

|  |  |
| --- | --- |
| **FOI NO: 1525** | **Date Received: 11 May 2020** |
| **Request :**  1a) How many continuing healthcare assessments for adults did your CCG carry out between 01.01.2019 - 01.05.2019  1b) How many continuing healthcare assessments for adults did your CCG carry out between 01.01.2020-01.05.2020    2a) Between 01.01.2019-01.05.2019 how many adults in your CCG received fully funded NHS Continuing Healthcare packages of care?    2b) Between 01.01.2020-01.05.2020 how many adults in your CCG received fully funded NHS Continuing Healthcare packages of care?    3a) Between 01.01.2019-01.05.2019 what was the actual amount spent on continuing healthcare for adults ?  3b) Between 01.01.2020-01.05.2020 what was the actual amount spent on continuing healthcare for adults?  4a) Between 01.01.2019 – 01.05.2019 what was the actual amount spent by your CCG for those adults in receipt of:  a) NHS fully funded nursing home care?  b)"Care at Home" - NHS Continuing Healthcare packages of care which enabled patients to remain at home?  4b) Between 01.01.2020-01.05.2020 what was the actual amount spent by your CCG in for those adults in receipt of:  a) NHS fully funded nursing home care?  b)"Care at Home" - NHS Continuing Healthcare packages of care which enabled patients to remain at home? | |
| **Response :**  1a) How many continuing healthcare assessments for adults did your CCG carry out between 01.01.2019 - 01.05.2019? 86 continuing healthcare assessments were completed in Barnsley between 01/01/2019 – 01/05/2019.    1b) How many continuing healthcare assessments for adults did your CCG carry out between 01.01.2020-01.05.2020 55 continuing healthcare assessments were completed in Barnsley between 01/01/2020 – 01/05/2020. Please note that from the 19th March no new assessments or reviews have been undertaken due to the COVID19 outbreak.    2a) Between 01.01.2019-01.05.2019 how many adults in your CCG received fully funded NHS Continuing Healthcare packages of care? 399 patients received fully funded NHS Continuing Healthcare packages between 01/01/2019 – 01/05/2019. Please note this figure also includes patients who received interim funding pending decision of their Continuing Healthcare assessment outcome at panel.    2b) Between 01.01.2020-01.05.2020 how many adults in your CCG received fully funded NHS Continuing Healthcare packages of care? 591 patients received fully funded NHS Continuing Healthcare packages between 01/01/2020 – 01/05/2020. Please note this figure also includes any new care package or increase in any existing care package due to the coronavirus to ensure patient safety during this period.    “Please note the cost for year 2020 may not be up to date due to the current COVID19 pandemic which means DST are not currently carried out and there may be some delay in our data flow. Also 2020/21 uplifts may not have been fully actioned on our system.    Q3 – The below figures include costs for specialist placements, day care, respite and supported living along with home care and residential / nursing placements.  3a) Between 01.01.2019-01.05.2019 what was the actual amount spent on continuing healthcare for adults ? £5.097m  3b) Between 01.01.2020-01.05.2020 what was the actual amount spent on continuing healthcare for adults? £5.077m  4a) Between 01.01.2019 – 01.05.2019 what was the actual amount spent by your CCG for those adults in receipt of:  a) NHS fully funded nursing home care? Please note the cost includes residential, residential EMI, nursing and nursing EMI costs and 1:1 supervisions £2.180m  b)"Care at Home" - NHS Continuing Healthcare packages of care which enabled patients to remain at home? Please note this figure includes Personal Health Budgets and home care £1.988m  4b) Between 01.01.2020-01.05.2020 what was the actual amount spent by your CCG in for those adults in receipt of:  a) NHS fully funded nursing home care? Please note the cost includes residential, residential EMI, nursing and nursing EMI costs and 1:1 supervisions £2.372m  b)"Care at Home" - NHS Continuing Healthcare packages of care which enabled patients to remain at home? Please note this figure includes Personal Health Budgets and home care £1.915m” | |

|  |  |
| --- | --- |
| **FOI NO: 1526** | **Date Received: 11 May 2020** |
| **Request :**  A list of pharmaceutical products/drugs that your primary care organisation currently holds rebate agreements for.  I would like to request the product names (brand and generic when applicable) with start and finish dates and I fully understand that the financial details of the rebates would be considered commercially confidential. | |
| **Response :**  Manufacturer and Drug listed below:  Aspire Pharma Ltd  Biquelle XL  Aspire Pharma Ltd  Gatalin XL  Aspire Pharma Ltd  Repinex XL (ropinirole XL)  Aymes  Aymes products  Boehringer Ingelheim Limited  Spiolto Respimat  Chiesi Ltd  Clenil Modulite  Ethypharm (formerly DB Ashbourne)  Fencino (fentanyl patches)  Ethypharm (formerly DB Ashbourne)  Pipexus  Fontus  Luventa XL (galantamine XL)  Intra-Pharm  Carbocisteine sachets  Menarini Diagnostics  GlucoMen Areo Sensors  MSD  Sitagliptin (Januvia)  Sandoz  AirFluSal Forspiro  Sandoz  AirFluSal MDI  Sanofi  Ins Apidra  Sanofi  Ins Lantus  Takeda  Leuprorelin (Prostap) | |

|  |  |
| --- | --- |
| **FOI NO: 1527** | **Date Received: 21 May 2020** |
| **Request :**  "Simon Stevens and Amanda Pritchard wrote to all NHS trusts and CCG Chief Executives on the 29th of April to advise that employers, on a precautionary basis, should conduct risk assessments for staff at greater risk during the COVID-19 pandemic and to act accordingly.  Has your organisation completed risk assessments on all Black Asian and Minority Ethnic (BAME) staff?  AND  What precautions, if any, have you put in place to protect BAME staff once they've been risk assessed?" | |
| **Response :**  The CCG is observing the government guidance to work from home where possible. In the event of staff having to return to office based working, risk assessments for all individuals will be undertaken in advance. | |